The PE Ratio as of December 2024 (TTM) for Olema Pharmaceuticals, Inc. (OLMA) is -2.76

According to Olema Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.76. This represents a change of -50.20% compared to the average of -5.54 of the last 4 quarters.

Olema Pharmaceuticals, Inc. (OLMA) Historical PE Ratio (quarterly & annually)

How has OLMA PE Ratio performed in the past?

The mean historical PE Ratio of Olema Pharmaceuticals, Inc. over the last ten years is -144.38. The current -2.76 PE Ratio has changed 91.17% with respect to the historical average. Over the past ten years (40 quarters), OLMA's PE Ratio was at its highest in in the December 2022 quarter at -0.98. The PE Ratio was at its lowest in in the December 2019 quarter at -169.82.

Olema Pharmaceuticals, Inc. (OLMA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Olema Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Olema Pharmaceuticals, Inc. (OLMA) Average PE Ratio

How has OLMA PE Ratio performed in the past?

The current PE Ratio of Olema Pharmaceuticals, Inc. (OLMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Olema Pharmaceuticals, Inc. (OLMA) PE Ratio vs. Peers

How is OLMA’s PE Ratio compared to its peers?

Olema Pharmaceuticals, Inc.’s PE Ratio is less than Sana Biotechnology, Inc. (-1.25), greater than Cullinan Oncology, Inc. (-4.82), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.26), less than Molecular Partners AG (-2.46), greater than Mineralys Therapeutics, Inc. (-3.92), less than AN2 Therapeutics, Inc. (-0.69), greater than Pharvaris N.V. (-7.39), less than PepGen Inc. (-1.45), greater than Gracell Biotechnologies Inc. (-29.25), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Monte Rosa Therapeutics, Inc. (-4.90), greater than Design Therapeutics, Inc. (-7.36), greater than Erasca, Inc. (-4.40), greater than Disc Medicine, Inc. (-18.46), greater than Larimar Therapeutics, Inc. (-3.90), greater than Fennec Pharmaceuticals Inc. (-140.94), greater than Orchestra BioMed Holdings, Inc. (-3.06), greater than Nuvectis Pharma, Inc. (-4.07), greater than Centessa Pharmaceuticals plc (-12.61),

Build a custom stock screener for Olema Pharmaceuticals, Inc. (OLMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Olema Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Olema Pharmaceuticals, Inc. (OLMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Olema Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.